FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1440-1441 May 25, 1995 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

It has been known for almost a century that testosterone and its intracellular mediator, dihydrotestosterone, control the development and function of the prostate gland. Huggins and his colleagues used this knowledge to show that medical or surgical castration can cause regression of prostate cancer. This discovery led to one of the first, if not the first, effective therapies for prostate cancer.¹ Unfortunately, prostate cancer continues to be a leading cause of death from cancer in men because the response to castration is usually brief, and few effective alternative therapies are available. Indeed, elucidation of the biology of this tumor lags . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Chen, S., Supakar, P. C., Vellanoweth, R. L., Song, C. S., Chatterjee, B., Roy, A. K. (1997). Functional Role of a Conformationally Flexible Homopurine/Homopyrimidine Domain of the Androgen Receptor Gene Promoter Interacting with SP1 and a Pyrimidine Single Strand DNA-Binding Protein. Mol. Endocrinol. 11: 3-15 [Abstract] [Full Text]